2616 Stock Overview
A biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
CStone Pharmaceuticals Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.76 |
| 52 Week High | HK$3.89 |
| 52 Week Low | HK$0.83 |
| Beta | 0.12 |
| 1 Month Change | -22.25% |
| 3 Month Change | 13.11% |
| 1 Year Change | 220.93% |
| 3 Year Change | -45.24% |
| 5 Year Change | -66.95% |
| Change since IPO | -78.54% |
Recent News & Updates
Revenues Working Against CStone Pharmaceuticals' (HKG:2616) Share Price Following 35% Dive
Apr 08
Analysts Are More Bearish On CStone Pharmaceuticals (HKG:2616) Than They Used To Be
Apr 01Recent updates
Revenues Working Against CStone Pharmaceuticals' (HKG:2616) Share Price Following 35% Dive
Apr 08Analysts Are More Bearish On CStone Pharmaceuticals (HKG:2616) Than They Used To Be
Apr 01There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 28% Share Price Rise
Feb 14Is CStone Pharmaceuticals (HKG:2616) Weighed On By Its Debt Load?
Dec 12There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 29% Share Price Rise
Oct 04Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified
May 12Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop
Mar 04Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet
Jan 18The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%
Oct 04Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 03Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 20Shareholder Returns
| 2616 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 4.2% | -2.6% | -0.3% |
| 1Y | 220.9% | 50.4% | 17.6% |
Return vs Industry: 2616 exceeded the Hong Kong Biotechs industry which returned 50.4% over the past year.
Return vs Market: 2616 exceeded the Hong Kong Market which returned 17.6% over the past year.
Price Volatility
| 2616 volatility | |
|---|---|
| 2616 Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 13.6% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in HK Market | 15.1% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2616's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2616's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 135 | Jason Yang | www.cstonepharma.com |
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company’s product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.
CStone Pharmaceuticals Fundamentals Summary
| 2616 fundamental statistics | |
|---|---|
| Market cap | HK$3.41b |
| Earnings (TTM) | -HK$96.82m |
| Revenue (TTM) | HK$432.26m |
8.7x
P/S Ratio-38.7x
P/E RatioIs 2616 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2616 income statement (TTM) | |
|---|---|
| Revenue | CN¥407.21m |
| Cost of Revenue | CN¥167.05m |
| Gross Profit | CN¥240.15m |
| Other Expenses | CN¥331.36m |
| Earnings | -CN¥91.21m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.067 |
| Gross Margin | 58.98% |
| Net Profit Margin | -22.40% |
| Debt/Equity Ratio | 87.4% |
How did 2616 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/22 10:02 |
| End of Day Share Price | 2025/04/22 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CStone Pharmaceuticals is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyi Chen | Goldman Sachs |
| Ling Wang | J.P. Morgan |
| Sean Wu | Morgan Stanley |